How to Test Human-Specific Combination Immunotherapies In Vivo
Por um escritor misterioso
Descrição
Learn how to evaluate combinations of human-specific checkpoint inhibitors in vivo, with double knock-in humanized drug target mouse models.
State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation
The next wave of cellular immunotherapies in pancreatic cancer - ScienceDirect
Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine: Molecular Therapy - Methods & Clinical Development
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma
Humanized Mouse Model Head to Head: hPBMC vs hCD34+
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Integration of In Vitro and In Vivo Models to Predict Cellular and Tissue Dosimetry of Nanomaterials Using Physiologically Based Pharmacokinetic Modeling
News: Editing Stem Cells In Vivo: A Major Stride in Gene Therapy for Blood Disorders - CRISPR Medicine
Role of NK cells to treat B-Cell Lymphoma
Antibodies for In Vivo Studies - LubioScience
Organoid Models of Tumor Immunology: Trends in Immunology
de
por adulto (o preço varia de acordo com o tamanho do grupo)
